NCT01376674
Completed
Not Applicable
Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer
ConditionsProstate Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- University Hospital Tuebingen
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- T-cell-immunity in time-course
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.
In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.
Investigators
Franziska Eckert
M.D.
University Hospital Tuebingen
Eligibility Criteria
Inclusion Criteria
- •Localised prostate cancer (node negative)
- •definitive radiotherapy
- •informed consent
Exclusion Criteria
- •medication including steroids or immunosuppressants
Outcomes
Primary Outcomes
T-cell-immunity in time-course
Time Frame: During and 3-6 months after radiotherapy
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Investigating the Tumour Immune Response of RadiotherapyCancerNCT05076500University of Manchester120
Active, not recruiting
Not Applicable
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic responseEUCTR2012-001786-32-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI19
Withdrawn
Phase 3
Acupuncture for the Immune System in Radiation Cancer PatientsGastrointestinal NeoplasmsUrogenital NeoplasmsNCT01422928British Columbia Cancer Agency
Completed
Not Applicable
Immune Boost In Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT02319408University Hospital Heidelberg36
Recruiting
Not Applicable
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric AdenocarcinomaHepatocellular CarcinomaBiliary Tract CarcinomaColorectal AdenocarcinomaNCT06349044Zhejiang Cancer Hospital120